Natixis Advisors LLC Purchases 10,795 Shares of Incyte Corporation $INCY

Natixis Advisors LLC grew its position in shares of Incyte Corporation (NASDAQ:INCY) by 31.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 44,730 shares of the biopharmaceutical company’s stock after purchasing an additional 10,795 shares during the quarter. Natixis Advisors LLC’s holdings in Incyte were worth $4,418,000 as of its most recent SEC filing.

Several other institutional investors have also recently modified their holdings of INCY. NewEdge Advisors LLC increased its position in shares of Incyte by 369.3% during the 1st quarter. NewEdge Advisors LLC now owns 12,597 shares of the biopharmaceutical company’s stock valued at $763,000 after purchasing an additional 9,913 shares during the last quarter. Jones Financial Companies Lllp boosted its holdings in Incyte by 15.1% during the 1st quarter. Jones Financial Companies Lllp now owns 4,944 shares of the biopharmaceutical company’s stock valued at $299,000 after acquiring an additional 648 shares during the period. Goldman Sachs Group Inc. boosted its holdings in Incyte by 6.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 814,559 shares of the biopharmaceutical company’s stock valued at $49,322,000 after acquiring an additional 48,751 shares during the period. United Services Automobile Association purchased a new stake in Incyte during the 1st quarter valued at about $219,000. Finally, Focus Partners Wealth boosted its holdings in Incyte by 74.1% during the 1st quarter. Focus Partners Wealth now owns 21,024 shares of the biopharmaceutical company’s stock valued at $1,273,000 after acquiring an additional 8,951 shares during the period. 96.97% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the company. HC Wainwright restated a “buy” rating and set a $135.00 target price on shares of Incyte in a report on Thursday, May 21st. Sanford C. Bernstein assumed coverage on Incyte in a report on Thursday, May 21st. They set a “market perform” rating and a $99.00 target price for the company. Wall Street Zen cut Incyte from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 14th. Wells Fargo & Company dropped their target price on Incyte from $107.00 to $101.00 and set an “equal weight” rating for the company in a report on Wednesday, February 11th. Finally, Royal Bank Of Canada dropped their target price on Incyte from $95.00 to $92.00 and set a “sector perform” rating for the company in a report on Wednesday, February 11th. Nine research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $104.85.

Incyte Trading Down 1.7%

NASDAQ INCY opened at $100.64 on Tuesday. Incyte Corporation has a fifty-two week low of $66.74 and a fifty-two week high of $112.29. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.60 and a current ratio of 3.68. The stock has a 50 day simple moving average of $96.66 and a two-hundred day simple moving average of $99.03. The stock has a market cap of $20.11 billion, a P/E ratio of 14.21, a price-to-earnings-growth ratio of 0.99 and a beta of 0.79.

Incyte (NASDAQ:INCY) last released its earnings results on Tuesday, April 28th. The biopharmaceutical company reported $1.81 EPS for the quarter, beating analysts’ consensus estimates of $1.38 by $0.43. The company had revenue of $1.27 billion during the quarter, compared to analysts’ expectations of $1.22 billion. Incyte had a return on equity of 26.66% and a net margin of 26.71%.The firm’s revenue for the quarter was up 20.9% compared to the same quarter last year. During the same quarter last year, the business posted $1.16 EPS. On average, analysts forecast that Incyte Corporation will post 6.65 earnings per share for the current year.

Key Headlines Impacting Incyte

Here are the key news stories impacting Incyte this week:

• Positive Sentiment: Incyte announced a definitive agreement to buy Vega Therapeutics for up to $2 billion, adding a late-stage bleeding-disorder asset to strengthen its hematology pipeline. Article Title
• Positive Sentiment: The deal is part of a broader push to bolster Incyte’s blood-disorder portfolio and diversify growth ahead of looming patent-expiry concerns for its key drug Jakafi. Article Title
• Neutral Sentiment: Multiple reports echoed the transaction and described it as a major biotech M&A move, reinforcing the market’s focus on pipeline expansion rather than operational weakness. Article Title

Insider Activity at Incyte

In other news, insider Pablo J. Cagnoni sold 18,667 shares of the firm’s stock in a transaction that occurred on Friday, April 17th. The stock was sold at an average price of $96.50, for a total value of $1,801,365.50. Following the completion of the transaction, the insider owned 262,692 shares in the company, valued at $25,349,778. This trade represents a 6.63% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 16.20% of the stock is currently owned by insiders.

About Incyte

Incyte Corporation is a Wilmington, Delaware–based biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation. Since its founding in 2002, Incyte has grown from a small research organization into a global enterprise, advancing a portfolio of internally developed and partnered assets. The company’s research and development efforts center on small-molecule drugs and biologics that modulate critical signaling pathways implicated in cancer, autoimmune disorders and rare diseases.

The company’s flagship product is Jakafi® (ruxolitinib), a Janus kinase (JAK) inhibitor approved for the treatment of myelofibrosis and polycythemia vera.